On November 25, 2024, Paula Cholmondeley, a Director at Lexeo Therapeutics Inc (LXEO, Financial), purchased 15,000 shares of the company, according to a SEC Filing. Following this transaction, the insider now owns a total of 30,627 shares in the company.
Lexeo Therapeutics Inc is a biotechnology company focused on developing gene therapy treatments for genetic and acquired diseases. The company aims to address unmet medical needs through innovative therapeutic solutions.
The recent purchase by the insider is part of a broader trend observed in the company's insider transaction history. Over the past year, there has been 1 insider buy and 7 insider sells. This indicates a relatively low level of insider buying activity compared to selling.
Shares of Lexeo Therapeutics Inc were trading at $6.99 each on the day of the insider's purchase, resulting in a market cap of $242.375 million for the company. The insider's acquisition of shares may reflect confidence in the company's future prospects.
For more information on the company's valuation metrics, such as GF Value, price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, investors can explore further details on the company's financial performance and market position.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
